



- (51) **International Patent Classification:**
C07D 471/04 (2006.01) *A61K 31/437* (2006.01)
- (21) **International Application Number:**
PCT/EP2011/065967
- (22) **International Filing Date:**
14 September 2011 (14.09.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (71) **Applicant (for all designated States except US):** **PROX-IMAGEN LIMITED** [GB/GB]; Proximagen Limited, 3rd Floor, 91-93 Farringdon Road, London, Greater London EC1M 3LN (GB).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **EVANS, David** [GB/GB]; c/o Proximagen Limited, 3rd Floor, 91-93 Farringdon Road, London, Greater London EC1M 3LN (GB). **CARLEY, Allison** [GB/GB]; c/o Proximagen Limited, 3rd Floor, 91-93 Farringdon Road, London, Greater London EC1M 3LN (GB). **STEWART, Alison** [GB/GB]; c/o Proximagen Limited, 3rd Floor, 91-93 Farringdon Road, London, Greater London EC1M 3LN (GB). **HIGGINSBOTTOM, Michael** [GB/GB]; c/o Proximagen Limited, 3rd Floor, 91-93 Farringdon Road, London, Greater London EC1M 3LN (GB). **SAVORY, Edward** [GB/GB]; c/o Proximagen Limited, 3rd Floor, 91-93 Farringdon Road, London, Greater London EC1M 3LN (GB). **SIMPSON, Iain** [GB/GB]; c/o Proximagen Limited, 3rd Floor, 91-93 Farringdon Road, London, Greater London EC1M 3LN (GB). **NILSSON, Marianne** [SE/SE]; c/o Swedish Orphan Biovitrum AB (publ), S-112 76 Stockholm (SE). **HARALDSSON, Martin** [SE/SE]; c/o Swedish Orphan Biovit-

rum AB (publ), S-112 76 Stockholm (SE). **NORDLING, Erik** [SE/SE]; c/o Swedish Orphan Biovitrum AB (publ), S-112 76 Stockholm (SE). **KOOLMEISTER, Tobias** [SE/SE]; c/o Swedish Orphan Biovitrum AB (publ), S-112 76 Stockholm (SE).

(74) **Agent:** **CLARKE, Lionel Paul**; Gill Jennings & Every LLP, The Broadgate Tower, 20 Primrose Street, London GB EC2A 2ES (GB).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** NEW ENZYME INHIBITOR COMPOUNDS

(57) **Abstract:** 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine; 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide; 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonylpiperazine; 4-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonylmorpholine; 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl-1,4-diazepane; ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; ethyl 1-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid; N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide; 4-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)morpholine; 1-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)piperazine; {4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}methanol; {4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}methanol; [(3R)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]methanol; methyl 4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxylate; N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxamide; 2-{4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}ethan-1-ol; methyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxylate; N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxamide; 1-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-yl}carbonyl)piperazine; 4-[1-(4-methylphenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine; 1-(4-chlorophenyl)-3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-4-ol; N-butyl-1-(4-chlorophenyl)-N-methyl-1H-pyrazolo[3,4-c]pyridin-3-amine; 1-[4-(fluoromethyl)phenyl]-3-(oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine; and 3-({4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}methyl)pyridine are useful for the inhibition of SSAO activity.

WO 2013/037411 A1

NEW ENZYME INHIBITOR COMPOUNDS


FIELD OF THE INVENTION

5 The present invention relates to compounds which are inhibitors of SSAO activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.

10

BACKGROUND ART

Semicarbazide-sensitive amine oxidase (SSAO) activity is an enzyme activity expressed by Vascular Adhesion Protein-1 (VAP-1) or Amine Oxidase, Copper Containing 3 (AOC3),
15 belongs to the copper-containing amine oxidase family of enzymes (EC.1.4.3.6). Therefore inhibitors of the SSAO enzyme may also modulate the biological functions of the VAP-1 protein. Members of this enzyme family are sensitive to inhibition by semicarbazide and utilize cupric ion and protein-derived topa quinone (TPQ) cofactor in the oxidative deamination of primary amines to aldehydes, hydrogen peroxide, and ammonia according to the following
20 reaction:



Known substrates for human SSAO include endogenous methylamine and aminoacetone as
25 well as some xenobiotic amines such as benzylamine [Lyles, *Int. J. Biochem. Cell Biol.* **1996**, 28, 259-274; Klinman, *Biochim. Biophys. Acta* **2003**, 1647(1-2), 131-137; Mátyus et al., *Curr. Med. Chem.* **2004**, 11(10), 1285-1298; O'Sullivan et al., *Neurotoxicology* **2004**, 25(1-2), 303-315]. In analogy with other copper-containing amine oxidases, DNA-sequence analysis and structure determination suggest that the tissue-bound human SSAO is a homodimeric
30 glycoprotein consisting of two 90-100 kDa subunits anchored to the plasma membrane by a single N-terminal membrane spanning domain [Morris et al., *J. Biol. Chem.* **1997**, 272, 9388-9392; Smith et al., *J. Exp. Med.* **1998**, 188, 17-27; Airene et al., *Protein Science* **2005**, 14, 1964-1974; Jakobsson et al., *Acta Crystallogr. D Biol. Crystallogr.* **2005**, 61(Pt 11), 1550-1562].

35

SSAO activity has been found in a variety of tissues including vascular and non-vascular smooth muscle tissue, endothelium, and adipose tissue [Lewinsohn, *Braz. J. Med. Biol. Res.* **1984**, *17*, 223-256; Nakos & Gossrau, *Folia Histochem. Cytobiol.* **1994**, *32*, 3-10; Yu et al., *Biochem. Pharmacol.* **1994**, *47*, 1055-1059; Castillo et al., *Neurochem. Int.* **1998**, *33*, 415-423; 5 Lyles & Pino, *J. Neural. Transm. Suppl.* **1998**, *52*, 239-250; Jaakkola et al., *Am. J. Pathol.* **1999**, *155*, 1953-1965; Morin et al., *J. Pharmacol. Exp. Ther.* **2001**, *297*, 563-572; Salmi & Jalkanen, *Trends Immunol.* **2001**, *22*, 211-216]. In addition, SSAO protein is found in blood plasma and this soluble form appears to have similar properties as the tissue-bound form [Yu et al., *Biochem. Pharmacol.* **1994**, *47*, 1055-1059; Kurkijärvi et al., *J. Immunol.* **1998**, *161*, 1549- 10 1557]. It has recently been shown that circulating human and rodent SSAO originates from the tissue-bound form [Göktürk et al., *Am. J. Pathol.* **2003**, *163*(5), 1921-1928; Abella et al., *Diabetologia* **2004**, *47*(3), 429-438; Stolen et al., *Circ. Res.* **2004**, *95*(1), 50-57], whereas in other mammals the plasma/serum SSAO is also encoded by a separate gene called AOC4 [Schwelberger, *J. Neural. Transm.* **2007**, *114*(6), 757-762].

15

The precise physiological role of this abundant enzyme has yet to be fully determined, but it appears that SSAO and its reaction products may have several functions in cell signalling and regulation. For example, recent findings suggest that SSAO plays a role in both GLUT4-mediated glucose uptake [Enrique-Tarancon et al., *J. Biol. Chem.* **1998**, *273*, 8025-8032; 20 Morin et al., *J. Pharmacol. Exp. Ther.* **2001**, *297*, 563-572] and adipocyte differentiation [Fontana et al., *Biochem. J.* **2001**, *356*, 769-777; Mercier et al., *Biochem. J.* **2001**, *358*, 335-342]. In addition, SSAO has been shown to be involved in inflammatory processes where it acts as an adhesion protein for leukocytes [Salmi & Jalkanen, *Trends Immunol.* **2001**, *22*, 211-216; Salmi & Jalkanen, in "Adhesion Molecules: Functions and Inhibition" K. Ley (Ed.), 25 **2007**, pp. 237-251], and might also play a role in connective tissue matrix development and maintenance [Langford et al., *Cardiovasc. Toxicol.* **2002**, *2*(2), 141-150; Göktürk et al., *Am. J. Pathol.* **2003**, *163*(5), 1921-1928]. Moreover, a link between SSAO and angiogenesis has recently been discovered [Noda et al., *FASEB J.* **2008**, *22*(8), 2928-2935], and based on this link it is expected that inhibitors of SSAO have an anti-angiogenic effect.

30

Several studies in humans have demonstrated that SSAO activity in blood plasma is elevated in conditions such as congestive heart failure, diabetes mellitus, Alzheimer's disease, and inflammation [Lewinsohn, *Braz. J. Med. Biol. Res.* **1984**, *17*, 223-256; Boomsma et al., *Cardiovasc. Res.* **1997**, *33*, 387-391; Ekblom, *Pharmacol. Res.* **1998**, *37*, 87-92; Kurkijärvi et al., *J. Immunol.* **1998**, *161*, 1549-1557; Boomsma et al., *Diabetologia* **1999**, *42*, 233-237; 35


Meszaros et al., *Eur. J. Drug Metab. Pharmacokinet.* **1999**, *24*, 299–302; Yu et al., *Biochim. Biophys. Acta* **2003**, *1647(1–2)*, 193–199; Mátyus et al., *Curr. Med. Chem.* **2004**, *11(10)*, 1285–1298; O'Sullivan et al., *Neurotoxicology* **2004**, *25(1–2)*, 303–315; del Mar Hernandez et al., *Neurosci. Lett.* **2005**, *384(1–2)*, 183–187]. The mechanisms underlying these alterations of enzyme activity are not clear. It has been suggested that reactive aldehydes and hydrogen peroxide produced by endogenous amine oxidases contribute to the progression of cardiovascular diseases, diabetic complications and Alzheimer's disease [Callingham et al., *Prog. Brain Res.* **1995**, *106*, 305–321; Ekblom, *Pharmacol. Res.* **1998**, *37*, 87–92; Yu et al., *Biochim. Biophys. Acta* **2003**, *1647(1–2)*, 193–199; Jiang et al., *Neuropathol Appl Neurobiol.* **2008**, *34(2)*, 194–204]. Furthermore, the enzymatic activity of SSAO is involved in the leukocyte extravasation process at sites of inflammation where SSAO has been shown to be strongly expressed on the vascular endothelium [Salmi et al., *Immunity* **2001**, *14(3)*, 265–276; Salmi & Jalkanen, in “*Adhesion Molecules: Functions and Inhibition*” K. Ley (Ed.), **2007**, pp. 237–251]. Accordingly, inhibition of SSAO has been suggested to have a therapeutic value in the prevention of diabetic complications and in inflammatory diseases [Ekblom, *Pharmacol. Res.* **1998**, *37*, 87–92; Salmi et al., *Immunity* **2001**, *14(3)*, 265–276; Salter-Cid et al., *J. Pharmacol. Exp. Ther.* **2005**, *315(2)*, 553–562].

SSAO knockout animals are phenotypically overtly normal but exhibit a marked decrease in the inflammatory responses evoked in response to various inflammatory stimuli [Stolen et al., *Immunity* **2005**, *22(1)*, 105–115]. In addition, antagonism of its function in wild type animals in multiple animal models of human disease (e.g. carrageenan-induced paw inflammation, oxazolone-induced colitis, lipopolysaccharide-induced lung inflammation, collagen-induced arthritis, endotoxin-induced uveitis) by the use of antibodies and/or small molecules has been shown to be protective in decreasing the leukocyte infiltration, reducing the severity of the disease phenotype and reducing levels of inflammatory cytokines and chemokines [Kirton et al., *Eur. J. Immunol.* **2005**, *35(11)*, 3119–3130; Salter-Cid et al., *J. Pharmacol. Exp. Ther.* **2005**, *315(2)*, 553–562; McDonald et al., *Annual Reports in Medicinal Chemistry* **2007**, *42*, 229–243; Salmi & Jalkanen, in “*Adhesion Molecules: Functions and Inhibition*” K. Ley (Ed.), **2007**, pp. 237–251; Noda et al., *FASEB J.* **2008** *22(4)*, 1094–1103; Noda et al., *FASEB J.* **2008**, *22(8)*, 2928–2935]. This anti-inflammatory protection seems to be afforded across a wide range of inflammatory models all with independent causative mechanisms, rather than being restricted to one particular disease or disease model. This would suggest that SSAO may be a key nodal point for the regulation of the inflammatory response, and it is therefore likely that SSAO inhibitors will be effective anti-inflammatory drugs in a wide range of human diseases.

SSAO (VAP-1) is up regulated in gastric cancer and has been identified in the tumour vasculature of human melanoma, hepatoma and head and neck tumours (Yoong KF, McNab G, Hubscher SG, Adams DH. (1998), *J Immunol* **160**, 3978–88.; Irjala H, Salmi M, Alanen K, Gre´nman R, Jalkanen S (2001), *Immunol.* **166**, 6937–6943; Forster-Horvath C, Dome B, Paku S, et al. (2004), *Melanoma Res.* **14**, 135–40.). One report (Marttila-Ichihara F, Castermans K, Auvinen K, Oude Egbrink MG, Jalkanen S, Griffioen AW, Salmi M. (2010), *J Immunol.* **184**, 3164-3173.) has shown that mice bearing enzymically inactive VAP-1 grow melanomas more slowly, and have reduced tumour blood vessel number and diameter. The reduced growth of these tumours was also reflected in the reduced (by 60-70%) infiltration of myeloid suppressor cells. Encouragingly VAP-1 deficiency had no effect on vessel or lymph formation in normal tissue.

Small molecules of different structural classes have previously been disclosed as SSAO inhibitors, for example in WO 02/38153 (tetrahydroimidazo[4,5-c]pyridine derivatives), in WO 03/006003 (2-indanylhydrazine derivatives), in WO 2005/014530 (allylhydrazine and hydroxylamine (aminoxy) compounds) and in WO 2007/120528 (allylamino compounds). Additional SSAO inhibitors are disclosed in PCT/EP2009/062011 and PCT/EP2009/062018.

Our co-pending International Patent Application No.: PCT/EP2011/053818 relates to SSAO inhibitors of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof:



wherein

R¹ is phenyl or 6-membered heteroaryl, optionally substituted with one or more substituents selected from halogen, cyano, C₁₋₄-alkyl, halo-C₁₋₄-alkyl, C₁₋₄alkoxy-C₁₋₄alkyl, hydroxy-C₁₋₄-alkyl, cyano-C₁₋₄-alkyl, amino-C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl, di(C₁₋₄-alkyl)amino-C₁₋₄-alkyl, -NR^{4A}R^{4B}, -NR⁶C(O)OR⁵, -NR⁶C(O)R⁵, -NR⁶C(O)NR^{4A}R^{4B}, -C(O)NR^{4A}R^{4B}, -C(O)R⁵, -C(O)OR⁵, and -NR⁶S(O)₂R⁵;

30

A is a bond;

R² is -B-Q-[R³]_n or -B-R³;

35 wherein n = 1, 2, 3, or 4

B is a bond, O, NR⁴, -C(O)- or C₁₋₃-alkylene;

Q is saturated or partially unsaturated monocyclic 3-7 membered heterocyclic or C₃₋₇-
5 cycloalkyl ring;

when R² is -B-Q-[R³]_n, R³ is selected from hydrogen, halogen, cyano, amino, hydroxyl, oxo, C₁₋₄-alkyl, halo-C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄alkoxy-C₁₋₄alkyl, hydroxy-C₁₋₄-alkyl, cyano-C₁₋₄-alkyl, amino-C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl, di(C₁₋₄-alkyl)amino-C₁₋₄-alkyl, -NR^{4A}R^{4B}, -
10 NR⁶C(O)OR⁵, -NR⁶C(O)R⁵, -NR⁶C(O)NR^{4A}R^{4B}, -C(O)NR^{4A}R^{4B}, -C(O)R⁵, -C(O)OR⁵, -NR⁶S(O)₂R⁵, -S(O)₂R⁵, phenyl-C₁₋₄-alkyl and heteroaryl-C₁₋₄-alkyl, and wherein any phenyl or heteroaryl residue is optionally substituted with one or more substituents selected from halogen, cyano, C₁₋₄-alkyl, halo-C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄alkoxy-C₁₋₄alkyl, hydroxy-C₁₋₄-alkyl, cyano-C₁₋₄-alkyl, amino-C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl, di(C₁₋₄-alkyl)amino-C₁₋₄-alkyl, -NR^{4A}R^{4B}, -NR⁶C(O)OR⁵, -NR⁶C(O)R⁵, -NR⁶C(O)NR^{4A}R^{4B}, -C(O)NR^{4A}R^{4B}, -C(O)R⁵, -
15 C(O)OR⁵, -NR⁶S(O)₂R⁵;


when R² is -B-R³, R³ is selected from amino, C₁₋₄-alkoxy, C₁₋₄alkoxy-C₁₋₄alkyl, hydroxy-C₁₋₄-alkyl, cyano-C₁₋₄-alkyl, amino-C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl, di(C₁₋₄-alkyl)amino-C₁₋₄-alkyl, -NR^{4A}R^{4B}, -NR⁶C(O)OR⁵, -NR⁶C(O)R⁵, -NR⁶C(O)NR^{4A}R^{4B}, -C(O)NR^{4A}R^{4B},
20 -C(O)R⁵, -NR⁶S(O)₂R⁵, phenyl-C₁₋₄-alkyl and heteroaryl-C₁₋₄-alkyl, and wherein any phenyl or heteroaryl residue is optionally substituted with one or more substituents selected from halogen, cyano, C₁₋₄-alkyl, halo-C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄alkoxy-C₁₋₄alkyl, hydroxy-C₁₋₄-alkyl, cyano-C₁₋₄-alkyl, amino-C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl, di(C₁₋₄-alkyl)amino-C₁₋₄-alkyl, -NR^{4A}R^{4B}, -NR⁶C(O)OR⁵, -NR⁶C(O)R⁵, -NR⁶C(O)NR^{4A}R^{4B}, -C(O)NR^{4A}R^{4B}, -C(O)R⁵, -
25 C(O)OR⁵, -NR⁶S(O)₂R⁵, provided that when R² is -B-R³, and B is a bond and R³ is -C(O)R⁵, then R⁵ is not hydrogen;

R^{4A}, R^{4B} and R⁵ are each independently selected from hydrogen, C₁₋₄-alkyl, hydroxy-C₁₋₄-alkyl, halo-C₁₋₄-alkyl, cyano-C₁₋₄-alkyl, amino-C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl, di(C₁₋₄-alkyl)-amino-C₁₋₄-alkyl or C₁₋₄alkoxy-C₁₋₄alkyl; or R^{4A} and R^{4B} together with the nitrogen to which they are attached form a cyclic amino group such as a piperidinyl, piperazinyl, N-substituted piperazinyl, morpholinyl or homopiperidinyl group;

R^{4A1} is selected from C₁₋₄-alkyl, hydroxy-C₁₋₄-alkyl, halo-C₁₋₄-alkyl, cyano-C₁₋₄-alkyl, amino-C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl, di(C₁₋₄-alkyl)amino-C₁₋₄-alkyl or C₁₋₄alkoxy-C₁₋₄alkyl; or R^{4A1} and R^{4B} together with the nitrogen to which they are attached form a cyclic amino group such as a piperidinyl, piperazinyl, N-substituted piperazinyl, morpholinyl or
 5 homopiperidinyl group;

R⁶ is hydrogen or C₁₋₄-alkyl; and

X is selected from the radicals of formulae (1-16) wherein the bond marked * is attached to
 10 R^{1A}- and the bond marked ** is attached to -R²:



wherein Y is selected from hydrogen, hydroxyl, amino, -NHR⁶, -OCH₃;

15 Z is selected from hydrogen, fluorine, hydroxyl, C₁₋₄-alkoxy, halo-C₁₋₄-alkyl, CONH₂, cyano, SO₂NH₂, amino, -NHR⁶;

W is selected from H, C₁₋₄-alkyl, halo-C₁₋₄-alkyl;

Brief Description of the Invention

The present invention relates to a group of specific compounds falling within the general disclosure of PCT/EP2011/053818, but not specifically exemplified therein. The present
5 compounds have the utilities disclosed herein.

Detailed Description of the Invention

According to the invention there is provided a compound selected from the group consisting
10 of:

- 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine;
3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate;
1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one;
15 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one;
N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;
N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;
20 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide;
1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine;
4-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine;
1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane;
25 ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate;
ethyl 1-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate;
1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid ;
N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-
30 carboxamide;
4-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)morpholine;
1-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)piperazine;
{4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}methanol;
35 {4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methanol;

[(3R)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]methanol;
methyl 4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxylate;
N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-
carboxamide;
5 2-{4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}ethan-1-ol;
methyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxylate;
N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-
carboxamide;
1-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-yl}carbonyl)piperazine;
10 4-[1-(4-methylphenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine;
1-(4-chlorophenyl)-3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-4-ol;
N-butyl-1-(4-chlorophenyl)-N-methyl-1H-pyrazolo[3,4-c]pyridin-3-amine;
1-[4-(fluoromethyl)phenyl]-3-(oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine;
3-({4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}methyl)pyridine;
15
and pharmaceutically acceptable salts thereof.

It is expected that compounds of the invention may be prepared in the form of hydrates, and solvates. Any reference herein, including the claims herein, to “compounds with which the
20 invention is concerned” or “compounds of the invention” or “the present compounds”, and the like, includes reference to salts, hydrates, and solvates of such compounds. The term ‘solvate’ is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term ‘hydrate’ is employed when said solvent is water.

25 Individual compounds of the invention may exist in an amorphous form and /or several polymorphic forms and may be obtained in different crystal habits. Any reference herein, including the claims herein, to “compounds with which the invention is concerned” or “compounds of the invention” or “the present compounds”, and the like, includes reference to
30 the compounds irrespective of amorphous or polymorphic form.

DEFINITIONS

The following definitions shall apply throughout the specification and the appended claims, unless otherwise stated or indicated.

As used herein, the term “compound of the invention” refers to the 30 compounds listed above, and includes their pharmaceutically acceptable salts, hydrates, and solvate.

“Pharmaceutically acceptable” means being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.

“Treatment” as used herein includes prophylaxis of the named disorder or condition, or amelioration or elimination of the disorder once it has been established.

“An effective amount” refers to an amount of a compound that confers a therapeutic effect on the treated subject. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).

“Prodrugs” refers to compounds that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention. A prodrug may be inactive when administered to a subject in need thereof, but is converted *in vivo* to an active compound of the invention. Prodrugs are typically rapidly transformed *in vivo* to yield the parent compound of the invention, e.g. by hydrolysis in the blood. The prodrug compound usually offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see Silverman, R. B., *The Organic Chemistry of Drug Design and Drug Action*, 2nd Ed., Elsevier Academic Press (2004), pp. 498-549). Prodrugs of a compound of the invention may be prepared by modifying functional groups, such as a hydroxy, amino or mercapto groups, present in a compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compound of the invention. Examples of prodrugs include, but are not limited to, acetate, formate and succinate derivatives of hydroxy functional groups or phenyl carbamate derivatives of amino functional groups.

Throughout the specification and the appended claims, a given chemical formula or name shall also encompass all salts, hydrates, solvates, N-oxides and prodrug forms thereof. Further, a given chemical formula or name shall encompass all tautomeric and stereoisomeric forms thereof. Tautomers include enol and keto forms. Stereoisomers include enantiomers and

diastereomers. Enantiomers can be present in their pure forms, or as racemic (equal) or unequal mixtures of two enantiomers. Diastereomers can be present in their pure forms, or as mixtures of diastereomers. Diastereomers also include geometrical isomers, which can be present in their pure *cis* or *trans* forms or as mixtures of those.

5

The compounds of the invention may be used as such or, where appropriate, as pharmacologically acceptable salts (acid or base addition salts) thereof. The pharmacologically acceptable addition salts mentioned below are meant to comprise the therapeutically active non-toxic acid and base addition salt forms that the compounds are able to form. Compounds
10 that have basic properties can be converted to their pharmaceutically acceptable acid addition salts by treating the base form with an appropriate acid. Exemplary acids include inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulphuric acid, phosphoric acid; and organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic
15 acid, benzenesulphonic acid, toluenesulphonic acid, methanesulphonic acid, trifluoroacetic acid, fumaric acid, succinic acid, malic acid, tartaric acid, citric acid, salicylic acid, *p*-aminosalicylic acid, pamoic acid, benzoic acid, ascorbic acid and the like. Exemplary base addition salt forms are the sodium, potassium, calcium salts, and salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, and amino acids,
20 such as, e.g. arginine and lysine. The term addition salt as used herein also comprises solvates which the compounds and salts thereof are able to form, such as, for example, hydrates, alcoholates and the like.

In one aspect, the invention relates to a compound of the invention for use in therapy. The
25 compounds as defined above are useful as inhibitors of SSAO activity. As such, they are useful in the treatment or prevention of conditions and diseases in which inhibition of SSAO activity is beneficial. More specifically, they are useful for the treatment or prevention of inflammation, inflammatory diseases, immune or autoimmune disorders, or inhibition of tumour growth.

30

In particular, it is believed that the compounds of the invention are useful for the treatment or prevention of arthritis (such as rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis and psoriatic arthritis), synovitis, vasculitis, conditions associated with inflammation of the bowel (such as Crohn's disease, ulcerative colitis, inflammatory bowel disease and irritable
35 bowel syndrome), atherosclerosis, multiple sclerosis, Alzheimer's disease, vascular dementia,

pulmonary inflammatory diseases (such as asthma, chronic obstructive pulmonary disease and acute respiratory distress syndrome), fibrotic diseases (including idiopathic pulmonary fibrosis, cardiac fibrosis and systemic sclerosis (scleroderma)), inflammatory diseases of the skin (such as contact dermatitis, atopic dermatitis and psoriasis), systemic inflammatory response syndrome, sepsis, inflammatory and/or autoimmune conditions of the liver (such as autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, sclerosing cholangitis, and autoimmune cholangitis), diabetes (type I or II) and/or the complications thereof, chronic heart failure, congestive heart failure, ischemic diseases (such as stroke and ischemia-reperfusion injury), and myocardial infarction and/or the complications thereof.

10

It is believed that the compounds of the invention are especially useful for the treatment or prevention of vasculitis, including, but not limited to, giant cell arteritis, Takayasu's arteritis, Polyarteritis nodosa, Kawasaki disease, Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, Henoch-Schönlein purpura, cryoglobulinemia, cutaneous leukocytoclastic angiitis and primary angiitis of the central nervous system.

15

It is also believed that the compounds of the invention are especially useful for the treatment of rheumatoid arthritis, chronic obstructive pulmonary disease or atopic dermatitis.

In view of the evidence cited in the above introduction that VAP1 is up regulated in several cancers, including gastric cancer, melanoma, hepatoma and head and neck tumours and that mice bearing enzymatically inactive VAP-1 grow melanomas more slowly, and in view of the link between VAP1 and angiogenesis, it is also expected that the compounds of the invention are anti-angiogenic and therefore have utility in the treatment of cancers by inhibition of tumour growth.

25

The invention thus includes the compounds of the invention for use in the treatment or prevention of the above-mentioned conditions and diseases. The invention also includes the use of said compounds in the manufacture of a medicament for the treatment or prevention of the above-mentioned conditions and diseases. The invention furthermore includes methods for treatment or prevention of such conditions and diseases, comprising administering to a mammal, including man, in need of such treatment an effective amount of a compound as defined above.

30

Methods delineated herein include those wherein the subject is identified as in need of a particular stated treatment. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).

5

In other aspects, the methods herein include those further comprising monitoring subject response to the treatment administrations. Such monitoring may include periodic sampling of subject tissue, fluids, specimens, cells, proteins, chemical markers, genetic materials, etc. as markers or indicators of the treatment regimen. In other methods, the subject is prescreened or
10 identified as in need of such treatment by assessment for a relevant marker or indicator of suitability for such treatment.

In one embodiment, the invention provides a method of monitoring treatment progress. The method includes the step of determining a level of diagnostic marker (Marker) (e.g., any target
15 or cell type delineated herein modulated by a compound herein) or diagnostic measurement (e.g., screen, assay) in a subject suffering from or susceptible to a disorder or symptoms thereof delineated herein, in which the subject has been administered a therapeutic amount of a compound herein sufficient to treat the disease or symptoms thereof. The level of Marker determined in the method can be compared to known levels of Marker in either healthy normal
20 controls or in other afflicted patients to establish the subject's disease status. In preferred embodiments, a second level of Marker in the subject is determined at a time point later than the determination of the first level, and the two levels are compared to monitor the course of disease or the efficacy of the therapy. In certain preferred embodiments, a pre-treatment level of Marker in the subject is determined prior to beginning treatment according to this invention;
25 this pre-treatment level of Marker can then be compared to the level of Marker in the subject after the treatment commences, to determine the efficacy of the treatment.

In certain method embodiments, a level of Marker or Marker activity in a subject is determined at least once. Comparison of Marker levels, e.g., to another measurement of Marker level
30 obtained previously or subsequently from the same patient, another patient, or a normal subject, may be useful in determining whether therapy according to the invention is having the desired effect, and thereby permitting adjustment of dosage levels as appropriate. Determination of Marker levels may be performed using any suitable sampling/expression assay method known in the art or described herein. Preferably, a tissue or fluid sample is first
35 removed from a subject. Examples of suitable samples include blood, urine, tissue, mouth or

cheek cells, and hair samples containing roots. Other suitable samples would be known to the person skilled in the art. Determination of protein levels and/or mRNA levels (e.g., Marker levels) in the sample can be performed using any suitable technique known in the art, including, but not limited to, enzyme immunoassay, ELISA, radiolabeling/assay techniques, blotting/chemiluminescence methods, real-time PCR, and the like.

COMPOSITIONS

A currently preferred embodiment of the invention is a pharmaceutical composition comprising a compound of the invention, together with one or more pharmaceutically acceptable carriers and/or excipients.

For clinical use, the compounds of the invention are formulated into pharmaceutical formulations for various modes of administration. It will be appreciated that compounds of the invention may be administered together with a physiologically acceptable carrier, excipient, or diluent. The pharmaceutical compositions of the invention may be administered by any suitable route, preferably by oral, rectal, nasal, topical (including buccal and sublingual), sublingual, transdermal, intrathecal, transmucosal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.

Other formulations may conveniently be presented in unit dosage form, e.g., tablets and sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art of pharmacy. Pharmaceutical formulations are usually prepared by mixing the active substance, or a pharmaceutically acceptable salt thereof, with conventional pharmaceutically acceptable carriers, diluents or excipients. Examples of excipients are water, gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like. Such formulations may also contain other pharmacologically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers, and the like. Usually, the amount of active compounds is between 0.1-95% by weight of the preparation, preferably between 0.2-20% by weight in preparations for parenteral use and more preferably between 1-50% by weight in preparations for oral administration.

The formulations can be further prepared by known methods such as granulation, compression, microencapsulation, spray coating, etc. The formulations may be prepared by conventional


methods in the dosage form of tablets, capsules, granules, powders, syrups, suspensions, suppositories or injections. Liquid formulations may be prepared by dissolving or suspending the active substance in water or other suitable vehicles. Tablets and granules may be coated in a conventional manner. To maintain therapeutically effective plasma concentrations for extended periods of time, compounds of the invention may be incorporated into slow release formulations.

The dose level and frequency of dosage of the specific compound will vary depending on a variety of factors including the potency of the specific compound employed, the metabolic stability and length of action of that compound, the patient's age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the condition to be treated, and the patient undergoing therapy. The daily dosage may, for example, range from about 0.001 mg to about 100 mg per kilo of body weight, administered singly or multiply in doses, e.g. from about 0.01 mg to about 25 mg each. Normally, such a dosage is given orally but parenteral administration may also be chosen.

PREPARATION OF COMPOUNDS OF THE INVENTION

The compounds of the invention may be prepared by, or in analogy with, conventional methods. The preparation of intermediates and compounds according to the examples of the present invention may in particular be illuminated by the following Schemes. Definitions of variables in the structures in schemes herein are commensurate with those of corresponding positions in the formulas delineated herein.

10 **Scheme 1.** General synthetic routes for preparation of compounds of formula (Ia)




wherein W, Y, Z, R¹ and R² are as defined in formula (I);

Compounds of general formula (Ia) can easily be prepared from 1H-pyrrolo[2,3-c]pyridines (IIa) by either reaction with a ketone to introduce a functional group at R² followed by introduction of R¹ (for example by a Suzuki reaction) to give compounds of formula (IIIa / IVa), or by initial introduction of R¹ followed by introduction of a functional group at R² that can be modified to give alternative R², as in (Va). Compounds of formulae (IIIa), (IVa) and (Va) can easily be converted into compounds of general formula (Ia) by standard synthetic

methods. Alternatively, 4-Chloro-3-aminopyridines (VIa) can be cyclised with the appropriate aldehyde to give compounds of general formula (VIIa) followed by introduction of R^1 (for example by an arylation reaction). The latter approach is known to those skilled in the art, for example in Xu et al., *Synthesis*, 24, 3981-3987, 2008.

5

Scheme 2. General synthetic route for preparation of compounds of formula (Ic).



wherein Y, Z, R^1 , R^2 and R^3 are as defined in formula (I);

- 10 Compounds of general formula (Ic) can easily be prepared according to standard methods known in the scientific literature, for example, by the cyclisation of 3-halo-4-[(pyridin-4-yl)carbonyl] compounds of general formula (IIc) with hydrazines, or by cyclisation of compounds of general formula (IIIc) to give compounds of general formula (IVc), and subsequent introduction of R^1 (for example by an arylation reaction). Such methods are known to those skilled in the art, for example in Verma et al, *Tet. Lett.*, 50, 383, 2009 and Zhu et al.,
- 15 *BioOrg. Med. Chem. Lett.*, 15, 2441-2452, 2007.

Optionally, a compound of formula (I) can also be transformed into another compound of formula (I) in one or more synthetic steps.

20

The following abbreviations have been used:

Ac	acetyl
Ac ₂ O	Acetic anhydride
AcOH	acetic acid
aq	aqueous
Ar	aryl
Boc	tert-butoxycarbonyl
nBuLi	n-butyllithium
calcd	calculated
cat	catalytic
CDI	carbonyldiimidazole
conc	concentrated
d	day
DCE	dichloroethane
DCM	dichloromethane
DIBALH	Diisobutylaluminium hydride
DIPEA	diisopropylethylamine
DMAP	4-dimethylaminopyridine
DMF	dimethylformamide
EDC	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
ES+	electrospray ionization
EtOAc	ethyl acetate
EtOH	ethanol
h	hour(s)
HBTU	O-benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate
HOBt	1-hydroxybenzotriazole hydrate
HPLC	High Performance Liquid Chromatography
HRMS	High-Resolution Mass Spectrometry
IBX	2-Iodoxybenzoic acid
Int	Intermediate
LCMS	Liquid Chromatography Mass Spectrometry
LDA	lithium diisopropylamide
M	molar

Me	methyl
MeCN	Acetonitrile
MeOH	methanol
min	minute(s)
MS	Mass Spectrometry
NaBH(OAc) ₃	sodium triacetoxyborohydride
NBS	N-bromosuccinimide
NIS	N-iodosuccinimide
NMP	N-methylpyrrolidone
Ph	phenyl
PhMe	toluene
R _f	Retention time
RT	room temperature
sat	saturated
SCX	Strong Cation Exchange
SM	starting material
TFA	trifluoroacetic acid
THF	tetrahydrofuran


EXAMPLES AND INTERMEDIATE COMPOUNDS

Experimental Methods

5 Reactions were conducted at room temperature unless otherwise specified. Microwave reactions were performed with a Biotage microwave reactor using process vials fitted with aluminum caps and septa. Hydrogenations were performed using a Thales H-Cube. Preparative flash chromatography was performed on Merck silica gel 60 (230-400 mesh) or using a Flash Master Personal system equipped with Strata SI-1 silica gigatubes, or using a CombiFlash
10 Companion system equipped with RediSep silica columns. Reverse phase column chromatography was performed on a Gilson system (Gilson 321 pump and Gilson FC204 fraction collector) equipped with Merck LiChroprep[®] RP-18 (40-63um) columns. Reverse Phase HPLC was performed on a Gilson system with a UV detector equipped with Phenomenex Synergi Hydro RP 150 x 10 mm, or YMC ODS-A 100/150 x 20 mm columns.
15 The purest fractions were collected, concentrated and dried under vacuum. Compounds were typically dried in a vacuum oven at 40 °C prior to purity analysis. Compound analysis was performed by HPLC/LCMS using an Agilent 1100 HPLC system / Waters ZQ mass spectrometer connected to an Agilent 1100 HPLC system with a Phenomenex Synergi, RP-Hydro column (150 x 4.6 mm, 4 μm, 1.5 mL per min, 30 °C, gradient 5-100% MeCN (+0.085% TFA) in water (+0.1% TFA) over 7 min, 200-300 nm). Accurate masses (HRMS)
20 were measured using a Thermo Scientific LTQ Orbitrap XL equipped with an Advio TriVersa NanoMate electrospray ion source (during the analyses the calibration was checked by three masses. Spectra were acquired in positive electrospray mode. The acquired mass range was m/z 100-2000. Samples were dissolved in DMSO to give 10mM solutions which were then further diluted with MeOH or 10mM NH₄OAc in MeOH to ~0.1M solutions prior to analysis).
25 The values reported correspond to the protonated molecular ions (MH⁺). The compounds prepared were named using ACD Name 6.0, 7.0 or 10.0.


INTERMEDIATE 1

30 ***tert*-Butyl 4-{1*H*-pyrrolo[2,3-*c*]pyridin-3-yl}-1,2,3,6-tetrahydropyridine-1-carboxylate**



6-Azaindole (4.48 g, 37.9 mmol) was dissolved in MeOH (70 mL) and KOH (4.68 g, 83.4 mmol) and tert-butyl 4-oxopiperidine-1-carboxylate (8.31 g, 41.7 mmol) were added. The reaction mixture was heated at 70 °C for 18 h. The residue was partitioned between water (250 mL) and DCM (250 mL) and the aq phase was extracted with DCM (2 x 250 mL). The combined organic fractions were dried (MgSO₄) and concentrated *in vacuo* to give the title compound as a yellow foam (11.3 g, 99%). LCMS (ES⁺): 300.1 [MH]⁺.


INTERMEDIATE 2

tert-Butyl 4-{1*H*-pyrrolo[2,3-*c*]pyridin-3-yl}piperidine-1-carboxylate

10

Intermediate 1 (11.3 g, 37.7 mmol) was dissolved in EtOH (200 mL) and hydrogenated over 10% Pd/C in an H-cube at 90 °C and 90 bar. The reaction mixture was concentrated *in vacuo* to give the title compound as a yellow solid (11.1 g, 97%). LCMS (ES⁺): 302.1 [MH]⁺.


15 INTERMEDIATE 3

tert-Butyl 4-[1-(4-chlorophenyl)-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl]piperidine-1-carboxylate

Intermediate 2 (11.1 g, 36.7 mmol) was dissolved in DMF (60 mL) and 1-chloro-4-iodobenzene (10.5 g, 44.0 mmol), *N,N*-dimethylethylenediamine (789 μL, 7.33 mmol), K₃PO₄ (16.3 g, 77.0 mmol) and CuI (698 mg, 3.67 mmol) were added under nitrogen. The reaction mixture was heated in a microwave at 160 °C for 20 min and concentrated *in vacuo*. The residue was partitioned between water (250 mL) and DCM (250 mL) and the aq phase was extracted with DCM (2 x 250 mL). The combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound as a yellow solid (6.86 g, 45%). LCMS (ES⁺): 411.9 [MH]⁺, HPLC: R_f 5.91 min, 76% purity.

25


INTERMEDIATE 4

4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine

Intermediate 3 (6.86 g, 16.6 mmol) was dissolved in DCM (200 mL) and TFA (50 mL) and stirred for 2 h. The solvents were removed *in vacuo* and the residue was dissolved in 1 M aq Na₂CO₃ (200 mL) and extracted with DCM (3 x 200 mL). The combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound as a red gum (3.18 g, 61%). LCMS (ES⁺): 312.1 [MH]⁺. HPLC: Rf 3.61 min, 96% purity.

10

INTERMEDIATE 5

Ethyl 1-[(3-aminopyridin-4-yl)methyl]piperidine-4-carboxylate

3-Amino-pyridine-4-carbaldehyde (5.00 g, 40.9 mmol) was dissolved in DCM (60 mL), ethyl 4-piperidinecarboxylate (7.57 mL, 49.1 mmol) and NaBH(OAc)₃ (10.4 g, 49.1 mmol) were added and the reaction mixture was heated in a microwave reactor at 60 °C for 5 min. The reaction mixture was diluted with DCM (100 mL) and quenched with sat aq Na₂CO₃ (50 mL). The organic fraction was washed with sat aq NH₄Cl (30 mL). The combined aq fractions were extracted with DCM (2 x 50mL) and the combined organic fractions were dried (MgSO₄) and concentrated *in vacuo* to give the crude title compound as a yellow gum (11.3g). LCMS (ES⁺): 264.1 [MH]⁺.


20

INTERMEDIATES 6 to 12


Intermediates 6-12 were prepared similarly to Intermediate 5, by reductive amination of 3-amino-pyridine-4-carbaldehyde with the appropriate amine; see Table 1 below.

25


Table 1: Reductive aminations of 3-amino-pyridine-4-carbaldehyde



Int	Structure	Crude yield	LCMS (ES ⁺)	Intermediate Name
6		2.88 g 48%	266.1 [MH] ⁺	{4-[(3-Aminopyridin-4-yl)methyl]morpholin-3-yl} methyl acetate
7		666 mg 14%	224.0 [MH] ⁺	[(3R)-4-[(3-Aminopyridin-4-yl)methyl]morpholin-3-yl]methanol
8		5.77 g 44%	266.1 [MH] ⁺	{4-[(3-Aminopyridin-4-yl)methyl]morpholin-2-yl} methyl acetate
9		673 mg 85%	194.1 [MH] ⁺	4-{Butyl(methyl)amino}methyl} pyridin-3-amine
10		2.43 g 99%	252.1 [MH] ⁺	Methyl 4-[(3-aminopyridin-4-yl)methyl]morpholine-3-carboxylate
11		3.16 g 63%	266.1 [MH] ⁺	Methyl 2-{4-[(3-aminopyridin-4-yl)methyl]morpholin-3-yl} acetate

Int	Structure	Crude yield	LCMS (ES ⁺)	Intermediate Name
12		1.76 g 40%	250.1 [MH] ⁺	Methyl 1-[(3-aminopyridin-4-yl)methyl]piperidine-2-carboxylate

INTERMEDIATE 13


Ethyl 1-[1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate

- 5 Intermediate 5 (6.81 g, 25.9 mmol) was dissolved in AcOH (334 mL), cooled to 0 °C and a solution of NaNO₂ (1.78 g, 25.9 mmol) in water (2.72 mL) was added. The reaction mixture was stirred at 0 °C for 5 min and concentrated *in vacuo*. The residue was dissolved in EtOAc (200 mL), washed with sat aq Na₂CO₃ (2 x 100 mL), dried (MgSO₄) and concentrated in vacuo to give the crude title compound as a brown gum (12.2 g). LCMS (ES⁺): 275.1 [MH]⁺.







10

INTERMEDIATES 14 to 20

Intermediates 14-20 were prepared similarly to Intermediate 13, by cyclisation of Intermediates 6-12 with NaNO₂; see Table 2 below.

15 **Table 2: Cyclisation of 3-aminopyridines**

Int	Structure	SM / Crude yield	LCMS (ES ⁺)	Intermediate Name
-----	-----------	------------------------	----------------------------	-------------------


Int	Structure	SM / Crude yield	LCMS (ES ⁺)	Intermediate Name
14		Int 6 1.73 g 58%	277.1 [MH] ⁺	(4-{1H-Pyrazolo[3,4-c]pyridin-3-yl}morpholin-3-yl)methyl acetate
15		Int 7 194 mg 65%	235.1 [MH] ⁺	[(3R)-4-{1H-Pyrazolo[3,4-c]pyridin-3-yl}morpholin-3-yl]methanol
16		Int 8 3.85 g 64%	277.1 [MH] ⁺	(4-{1H-Pyrazolo[3,4-c]pyridin-3-yl}morpholin-2-yl)methyl acetate
17		Int 9 622 mg 88%	205.1 [MH] ⁺	N-Butyl-N-methyl-1H-pyrazolo[3,4-c]pyridin-3-amine
18		Int 10 1.97 g 74%	263.0 [MH] ⁺	Methyl 4-{1H-pyrazolo[3,4-c]pyridin-3-yl}morpholine-3-carboxylate
19		Int 11 2.00 g 100%	277.1 [MH] ⁺	2-(4-{1H-Pyrazolo[3,4-c]pyridin-3-yl}morpholin-3-yl)acetate

Int	Structure	SM / Crude yield	LCMS (ES ⁺)	Intermediate Name
20		Int 12 650 g 89%	261.1 [MH] ⁺	Methyl 1-{1H-pyrazolo[3,4-c]pyridin-3-yl}piperidine-2-carboxylate

INTERMEDIATES 21 to 22

Intermediates 21-22 were prepared similarly to Intermediate 3, by N-arylation of 1H-pyrazolo[3,4-c]pyridines; see Table 3 below.


5

Table 3: N-Arylation of 1H-pyrazolo[3,4-c]pyridines

Int	Structure	SM / Crude yield	LCMS (ES ⁺)	Intermediate Name
21		Int 14 51.0 mg 2%	367.0 [MH] ⁺	{4-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}methyl acetate
22		Int 16 260 mg 5%	367.0 [MH] ⁺	{4-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl acetate


INTERMEDIATE 23

10 **Methyl 4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxylate**




Intermediate 18 (1.98 g, 7.53 mmol), 4-chlorophenylboronic acid (2.36 g, 15.1 mmol), Cu(OAc)₂ (2.74 g, 15.1 mmol) and pyridine (3.03 mL, 37.7 mmol) were suspended in DCE (52 mL) and stirred overnight. The reaction mixture was purified by column chromatography to give the title compound as a dark yellow solid (552 mg, 20%). LCMS (ES⁺): 373.2 [MH]⁺. HPLC: Rf 5.23 min, 98.0% purity.

INTERMEDIATE 24

Methyl 2-[4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]acetate

Intermediate 19 (1.64 g, 5.94 mmol), 4-chlorophenylboronic acid (1.86 g, 11.9 mmol), Cu(OAc)₂ (2.16 g, 11.9 mmol) and pyridine (2.39 mL, 29.7 mmol) were suspended in DCE (41 mL) and stirred overnight. The reaction mixture was purified by column chromatography to give the title compound as a yellow gum (866 mg, 38%). LCMS (ES⁺): 387.3 [MH]⁺. HPLC: Rf 5.32 min, 100% purity.


INTERMEDIATE 25

4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxylic acid hydrochloride

Intermediate 23 (84.0 mg, 0.23 mmol) was dissolved in 1:1 THF/water (2 mL), LiOH/H₂O (20.8 mg, 0.50 mmol) was added and the reaction mixture was stirred for 3 h. The THF was removed *in vacuo* and the aq residue was acidified to pH 1 with 1 M aq HCl (1 mL) and


concentrated *in vacuo* to give the crude title compound as an orange gum (115 mg). LCMS (ES⁺): 359.2 [MH]⁺. HPLC: Rf 4.59 min, 97.1% purity.

INTERMEDIATE 26

5 **1-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxylic acid hydrochloride**

Intermediate 26 was prepared similarly to Intermediate 25, using Example 23 instead of
10 Intermediate 23, to give the crude title compound as a brown solid (332 mg). LCMS (ES⁺): 357.0 [MH]⁺.


INTERMEDIATE 27

Methyl 2-(3-nitropyridin-4-yl)acetate

15 3-Nitropyridine (5.00 g, 40.3 mmol) and methyl chloroacetate (7.30 g, 67.3 mmol) were dissolved in THF (50 mL) and added drop-wise to a slurry of KOtBu (18.1 g, 161 mmol) in THF (50 mL) at 0 °C. The reaction mixture was stirred at RT for 1 h, cooled to 0 °C and quenched with sat aq NH₄Cl (100 mL). The THF was removed *in vacuo* and the reaction
20 mixture was diluted with DCM (75 mL). The aq fraction was extracted with DCM (3 x 40 mL) and the combined organic fractions were washed with brine (100 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound as a dark brown oil (3.94 g, 50%). LCMS (ES⁺): 196.9 [MH]⁺.


25 INTERMEDIATE 28

Methyl 2-bromo-2-(3-nitropyridin-4-yl)acetate



Intermediate 27 (2.66 g, 13.6 mmol), NBS (2.65 g, 14.9 mmol) and azobisisobutyronitrile (66.8 mg, 0.41 mmol) were dissolved in CCl₄ (20 mL) and the reaction mixture was heated under reflux for 5 h and concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound as an orange oil (3.25 g, 87%). LCMS (ES⁺): 274.3, 276.3 [MH]⁺.

INTERMEDIATE 29


Methyl 2-(morpholin-4-yl)-2-(3-nitropyridin-4-yl) acetate

10

Intermediate 28 (2.00 g, 7.27 mmol) was dissolved in MeCN (30 mL), morpholine (944 μL, 10.9 mmol) was added and the reaction mixture was stirred overnight. The precipitate was removed by filtration and the filtrate was concentrated *in vacuo*. The residue was purified by normal phase column chromatography to give the title compound as a yellow solid (1.63 g, 80%). LCMS (ES⁺): 282.0 [MH]⁺.

15

INTERMEDIATE 30

Methyl 2-(3-aminopyridin-4-yl)- 2-(morpholin-4-yl)acetate


20

Intermediate 29 (989 mg, 3.52 mmol) was dissolved in EtOAc (33 mL) and MeOH (37 mL) and hydrogenated over 10% Pd/C using a Thales H-cube (55 °C, 1 bar). The reaction mixture was concentrated *in vacuo* to give the crude title compound as a brown oil (916 mg, 100%). LCMS (ES⁺): 252.0 [MH]⁺.

25

INTERMEDIATE 31


4-{1H-Pyrrolo[2,3-c]pyridin-3-yl}morpholine



Intermediate 30 (916 mg, 3.65 mmol) was dissolved in THF (10 mL), cooled to -78 °C and LiAlH₄ (2.28 mL, 2.4 M in THF, 5.47 mmol) was added. The reaction mixture was stirred at -78 °C for 1 h, further LiAlH₄ (759 μL, 2.4 M in THF, 1.82 mmol) was added and the reaction mixture was stirred at -78 °C for 1 h. The reaction mixture was quenched with 1 M aq NaOH, filtered through celite and concentrated *in vacuo*. The residue was purified by normal phase column chromatography to give the title compound (517 mg, 70%) as a pale yellow gum. LCMS (ES⁺): 204.0 [MH]⁺.

10 INTERMEDIATE 32

3-Iodo-4-methoxy-1H-pyrrolo[2,3-c]pyridine




4-Methoxy-6-azaindole (662 mg, 4.47 mmol) was dissolved in CHCl₃ (20 mL), NIS (1.06 g, 4.69 mmol) was added and the reaction mixture was stirred for 18 h. The precipitate was collected by filtration and the filtrate was concentrated *in vacuo*. The residue was dissolved in EtOAc (50 mL), washed with 10% aq sodium thiosulfate (50 mL), sat aq NaHCO₃ (50 mL) and water (50 mL), dried (MgSO₄), concentrated *in vacuo* and combined with the precipitate to give the title compound as a red solid (1.12 g, 91%). LCMS (ES⁺): 274.9 [MH]⁺. HPLC: Rf 3.98 min, 96% purity.

20

INTERMEDIATE 33

1-(3-Iodo-4-methoxy-1H-pyrrolo[2,3-c]pyridin-1-yl)ethan-1-one




25 Intermediate 32 (1.12 g, 4.09 mmol) was dissolved in DCM (30 mL) and DMAP (49.9 mg, 0.41 mmol), DIPEA (710 μL, 4.09 mmol) and Ac₂O (424 μL, 4.50 mmol) were added. The reaction mixture was stirred for 18 h, diluted with DCM (100 mL), washed with 1 M aq

Na₂CO₃ (100 ml) and water (100 mL), dried (MgSO₄) and concentrated *in vacuo* to give the title compound as an orange solid (1.25 g, 97%). LCMS (ES⁺): 316.9 [MH]⁺. HPLC: Rf 3.92 min, 97% purity.

5 INTERMEDIATE 34


tert-Butyl 4-{4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl}-1,2,3,6-tetrahydro pyridine-1-carboxylate



Intermediate 33 (1.14 g, 3.61 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate (1.12 g, 3.61 mmol) and Na₂CO₃ (1.15 g, 10.8 mmol) were dissolved in dioxane (15 mL) and water (3 mL) and Pd(PPh₃)₄ (624 mg, 0.54 mmol) was added. The reaction mixture was heated at 100 °C in a microwave reactor for 2 h, diluted with water (100 mL) and extracted with DCM (2 x 100 mL) and EtOAc (2 x 100 mL). The combined organic fractions were dried (MgSO₄), concentrated *in vacuo* and purified by column chromatography to give the title compound as a yellow solid (502 mg, 37%). LCMS (ES⁺): 330.0 [MH]⁺.

INTERMEDIATE 35


tert-Butyl 4-{4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl}piperidine-1-carboxylate



20 Intermediate 35 was prepared similarly to Intermediate 2, using Intermediate 34 instead of Intermediate 1, to give the title compound as a yellow gum (260 mg, 51%). LCMS (ES⁺): 332.1 [MH]⁺.

25 INTERMEDIATE 36

tert-Butyl 4-[1-(4-chlorophenyl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate




Intermediate 36 was prepared similarly to Intermediate 3, using Intermediate 35 instead of Intermediate 2, to give the title compound as a yellow solid (141 mg, 41%). LCMS (ES⁺): 442.0 [MH]⁺.

5

INTERMEDIATE 37

N-Methoxy-N-methyloxane-4-carboxamide




N,O-Dimethylhydroxylamine hydrochloride (1.23 g, 12.7 mmol) and N-methyl morpholine (3.80 mL, 34.5 mmol) were dissolved in DCM (20 mL) and a solution of oxane-4-carbonyl chloride (1.71 g, 11.5 mmol) in DCM (20 mL) was added drop-wise. The reaction mixture was stirred for 2 h, then diluted to 200 mL with DCM, washed with 1 M aq HCl (2 x 100 mL), 1M aq Na₂CO₃ (100 mL) and water (100 mL), dried (MgSO₄) and concentrated *in vacuo* to give the crude title compound as a yellow oil (1.87 g, 94%). LCMS (ES⁺): 174.1 [MH]⁺.

15

INTERMEDIATE 38

3-Fluoro-4-[(oxan-4-yl)carbonyl]pyridine




Diisopropylamine (1.50 mL, 10.8 mmol) was dissolved in THF (30 mL) and cooled to -78 °C under nitrogen. nBuLi (4.32 mL, 2.5 M in hexanes, 10.8 mmol) was added drop-wise and the resulting solution was stirred at -78 °C for 10 min, at 0 °C for 30 min and then re-cooled to -78 °C. 3-Fluoro-pyridine (0.93 mL, 10.8 mmol) was added drop-wise over 5 min and the reaction mixture was stirred for 2 h. A solution of Intermediate 37 (1.87 g, 10.8 mmol) in THF (15 mL) was added and the reaction mixture was allowed to warm to RT and stirred for 15 min. The reaction mixture was quenched with sat aq NH₄OAc (10 mL) and diluted with EtOAc (200 mL). The organic fraction was washed with water (2 x 50 mL), dried (MgSO₄) and concentrated *in vacuo* to give the crude title compound as an orange oil (1.45 g, 64%). LCMS

25

(ES⁺): 210.1 [MH]⁺.

INTERMEDIATE 39

3-(Oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine




5

Intermediate 38 (255 mg, 1.22 mmol) and hydrazine monohydrate (134 mg, 2.68 mmol) were dissolved in NMP (3 mL) and the reaction mixture was heated in a microwave at 160 °C for 20 min. The reaction mixture was purified by SCX to give the title compound as an orange oil (245 mg, 99%). LCMS (ES⁺): 204.1 [MH]⁺.

10

INTERMEDIATE 40


tert-Butyl 4-[(3-fluoropyridin-4-yl)(hydroxy)methyl]piperidine-1-carboxylate



Diisopropylamine (0.66 ml, 4.69 mmol) was dissolved in THF (30 ml) and cooled to -78 °C. nBuLi (2.13 ml, 2.20 M in cyclohexane, 4.69 mmol) was added drop-wise and the reaction mixture was stirred at -78 °C for 10 min, at 0 °C for 30 min, and re-cooled to -78 °C. 3-Fluoropyridine (0.40 ml, 4.69 mmol) was added drop-wise over 5 min, and the reaction mixture was stirred for 45 min. A solution of N-Boc-4-piperidinecarboxaldehyde (1.00 g, 4.69 mmol) in THF (10 ml) was added and the reaction mixture was warmed to RT and stirred for 15 min. The reaction mixture was quenched with sat aq NH₄OAc (10 mL), diluted with EtOAc (100 mL), washed with water (2 x 50 mL), dried (MgSO₄) and concentrated *in vacuo* to give the title compound as an orange oil (1.42 g, 98%). LCMS (ES⁺): 255.0 [MH-t-Bu]⁺.

INTERMEDIATE 41

tert-Butyl 4-[(3-fluoropyridin-4-yl)carbonyl]piperidine-1-carboxylate




25

Intermediate 40 (1.42 g, 4.58 mmol) and IBX (1.93 g, 6.88 mmol) were dissolved in DCE (30 mL) and the reaction mixture was stirred at 65 °C for 16 h. The reaction mixture was cooled and filtered and the filtrate was concentrated *in vacuo* to give the crude title compound (1.96 g) as a yellow liquid. LCMS (ES⁺): 209.1 [MH-Boc]⁺.

5


INTERMEDIATE 42

tert-Butyl 4-{1H-pyrazolo[3,4-c]pyridin-3-yl}piperidine-1-carboxylate

Intermediate 41 (1.42 g, 4.61 mmol) and hydrazine monohydrate (407 μl, 8.31 mmol) were dissolved in NMP (5 mL) and the reaction mixture was heated in a microwave reactor at 160 °C for 20 min and purified by SCX and column chromatography to give the title compound as a orange oil (1.15 g, 83%). LCMS (ES⁺): 303.1 [MH]⁺.

10


INTERMEDIATE 43

15 **tert-Butyl 4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-1-carboxylate**

Intermediate 43 was prepared similarly to Intermediate 3, using Intermediate 42 instead of Intermediate 2, to give the title compound as a brown gum (1.02 g, 67%). LCMS (ES⁺): 413.0 [MH]⁺.

20

INTERMEDIATE 44

4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine


Intermediate 43 (1.02 g, 2.46 mmol) was dissolved in DCM (50 mL) and TFA (10 mL) was added. The reaction mixture was stirred for 1 h, concentrated *in vacuo* and purified by SCX to

25

give the title compound as a brown oil (696 mg, 90%). LCMS (ES+): 313.0 [MH]⁺.

EXAMPLE 1

2,2,2-Trifluoroacetic acid; 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine




Intermediate 4 (200 mg, 0.64 mmol) was dissolved in DCM (5 mL) and tert-butyl N-(2-oxoethyl)carbamate (203 μ L, 1.28 mmol) was added. The reaction mixture was stirred for 1 h and NaBH(OAc)₃ (340 mg, 1.60 mmol) was added. The reaction mixture was stirred for 18 h and partitioned between 1 M aq Na₂CO₃ (50 mL) and DCM (50 mL). The aq phase was extracted with DCM (2 x 50 mL) and the combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography, dissolved in DCM (5 mL) and TFA (1 mL) and stirred for 3 h. The reaction mixture was concentrated *in vacuo*, dissolved in 1 M aq Na₂CO₃ (50 mL) and extracted with DCM (3 x 50 mL). The combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by reverse phase HPLC (TFA buffered) to give the title compound as a colourless gum (1.10 mg, 0.4%). HRMS (ESI⁺) calcd for C₂₀H₂₃ClN₄ 355.1684, found 355.1687. HPLC: R_f 3.31 min, 97% purity.

20

EXAMPLE 2

3-Aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate




Triphosgene (119 mg, 0.40 mmol) was dissolved in DCM (5 mL) and a solution of tert-butyl N-(3-hydroxypropyl)carbamate (211 mg, 1.20 mmol) and DIPEA (209 μ L, 1.20 mmol) in DCM (1 mL) was added. The reaction mixture was stirred for 3 h and a solution of Intermediate 4 (250 mg, 0.80 mmol) and DIPEA (209 μ L, 1.20 mmol) in DCM (1 mL) was

25


added. The reaction mixture was stirred for 3 d, diluted with EtOAc (50 mL) and washed with 10% aq citric acid (50 mL) and 1 M aq Na₂CO₃ (50 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography, dissolved in DCM (20 mL) and TFA (5 mL) and stirred for 2 h. The reaction mixture was concentrated *in vacuo*, dissolved in 1 M aq Na₂CO₃ (50 mL) and extracted with DCM (3 x 50 mL). The combined organic fractions were concentrated *in vacuo* and the residue was purified by column chromatography to give the title compound as a colourless gum (52.0 mg, 16%). HRMS (ESI+) calcd for C₂₂H₂₅ClN₄O₂ 413.1739, found 413.1739. HPLC: Rf 3.96 min, 98% purity.

10 EXAMPLE 3

1-{4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one; 2,2,2-trifluoroacetic acid

Intermediate 4 (200 mg, 0.64 mmol), 4-(dimethylamino)butanoic acid hydrochloride (140 mg, 0.83 mmol), HOBt (113 mg, 0.83 mmol) and DIPEA (290 μL, 1.67 mmol) were dissolved in DMF (5 mL) and EDC (160 mg, 0.83 mmol) was added. The reaction mixture was stirred for 18 h and concentrated *in vacuo*. The residue was dissolved in 1 M aq Na₂CO₃ (50 mL) and extracted with DCM (3 x 50 mL). The combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography and reverse phase HPLC (TFA buffered) to give the title compound as a colourless gum (37.0 mg, 11%). HRMS (ESI+) calcd for C₂₄H₂₉ClN₄O 425.2103, found 425.2109. HPLC: Rf 4.00 min, 98 % purity.

EXAMPLE 4


25 **5-Amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one**

Intermediate 4 (200 mg, 0.64 mmol) was dissolved in DMF (10 mL) and 5-[[tert-

butoxy)carbonyl]amino}pentanoic acid (181 mg, 0.83 mmol), HOBt (113 mg, 0.83 mmol) and EDC (160 mg, 0.83 mmol) were added. The reaction mixture was stirred for 3 d and concentrated *in vacuo*. The residue was dissolved in 1 M aq Na₂CO₃ (50 mL) and extracted with DCM (3 x 50 mL). The combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography and dissolved in DCM (10 mL) and TFA (2 mL) and stirred for 2 h. The reaction mixture was concentrated *in vacuo* and the residue was dissolved in 1 M aq Na₂CO₃ (50 mL) and extracted with DCM (3 x 50 mL). The combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography to give the title compound as a colourless gum (43.0 mg, 16%). HRMS (ESI+) calcd for C₂₃H₂₇ClN₄O 411.1946, found 411.1947. HPLC: R_f 3.84 min, 99% purity.

EXAMPLE 5


N-(2-Aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide



CDI (125 mg, 0.77 mmol) was dissolved in DCM (10 mL) and a solution of tert-butyl N-(2-aminoethyl)carbamate (123 mg, 0.77 mmol) and DIPEA (167 μL, 0.96 mmol) in DCM (1 mL) was added. The reaction mixture was stirred for 18 h, a solution of Intermediate 4 (200 mg, 0.64 mmol) and DIPEA (167 μL, 0.96 mmol) in DCM (1 mL) was added, and the reaction mixture was stirred for 24 h. The reaction mixture was diluted with EtOAc (50 mL), washed with 10% aq citric acid (50 mL) and 1 M Na₂CO₃ (50 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue was dissolved in DCM (5 mL) and TFA (1 mL) and stirred for 1 h. The reaction mixture was concentrated *in vacuo* and the residue was purified by reverse phase HPLC to give the title compound as a colourless gum (36.0 mg, 14%). HRMS (ESI+) calcd for C₂₁H₂₄ClN₅O 398.1742, found 398.1745. HPLC: R_f 3.71 min, 99% purity.

EXAMPLE 6

N-(3-Aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide




Example 6 (178 mg, 8%) was prepared similarly to Example 5, using tert-butyl N-(3-aminopropyl)carbamate instead of tert-butyl N-(2-aminoethyl)carbamate. HRMS (ESI+) calcd for C₂₂H₂₆ClN₅O 412.1899, found 412.1902. HPLC: R_f 3.82 min, 100% purity.

5

EXAMPLE 7


4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide



10 Example 7 (99.0 mg, 23%) was prepared similarly to Example 5, using (3-aminopropyl)dimethylamine instead of tert-butyl N-(2-aminoethyl)carbamate (and no deprotection step). HRMS (ESI+) calcd for C₂₄H₃₀ClN₅O 440.2212, found 440.2213. HPLC: R_f 3.99 min, 99.7% purity.

15 EXAMPLE 8


1-((4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl)carbonyl)piperazine



Triphosgene (111 mg, 0.37 mmol) was dissolved in DCM (10 mL) and a solution of *tert*-butyl
 20 1-piperazinecarboxylate (210 mg, 1.13 mmol) and DIPEA (215 μ L, 1.24 mmol) in DCM (2 mL) was added. The reaction mixture was stirred for 18 h and a solution of Intermediate 4 (351 mg, 1.13 mmol), DIPEA (215 μ L, 1.24 mmol) and DMAP (13.7 mg, 0.11 mmol) in DCM (2 mL) was added. The reaction mixture was stirred for 24 h, diluted with 1 M aq Na₂CO₃ (50 mL) and extracted with DCM (3 x 50 mL). The combined organic fractions were dried
 25 (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography,


dissolved in DCM (10 mL) and TFA (2.5 mL) and stirred for 1 h. The solvents were removed *in vacuo* and the residue was dissolved in 1 M aq Na₂CO₃ (50 mL) and extracted with DCM (3 x 50 mL). The combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by reverse phase HPLC to give the title compound as a white solid (54.0 mg, 11%). HRMS (ESI+) calcd for C₂₃H₂₆CIN₅O 424.1899, found 424.19. HPLC: Rf 3.93 min, 100% purity.

EXAMPLE 9

4-({4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine

Intermediate 4 (300 mg, 0.96 mmol), DIPEA (184 μ L, 1.06 mmol) and DMAP (11.7 mg, 0.10 mmol) were dissolved in DCM (10 mL) and 4-morpholinecarbonyl chloride (158 mg, 1.06 mmol) was added. The reaction mixture was stirred for 18 h, diluted with 1 M aq Na₂CO₃ (50 mL) and extracted with DCM (3 x 50 mL). The combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by reverse phase HPLC to give the title compound as a white solid (252 mg, 62%). HRMS (ESI+) calcd for C₂₃H₂₅CIN₄O₂ 425.1739, found 425.1742. HPLC: Rf 4.79 min, 96% purity.


EXAMPLE 10

1-({4-[1-(4-Chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane

Example 10 (70.0 mg, 20%) was prepared similarly to Example 8, using *tert*-butyl 1,4-diazepane-1-carboxylate instead of *tert*-butyl 1-piperazinecarboxylate. HRMS (ESI+) calcd for C₂₄H₂₈CIN₅O 438.2055, found 438.2056. HPLC: Rf 3.94 min, 100% purity.

EXAMPLE 11


Ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate



Intermediate 13 (3.49 g, 12.7 mmol), 4-chlorophenylboronic acid (3.98 g, 25.5 mmol), Cu(OAc)₂ (4.63 g, 25.5 mmol) and pyridine (5.13 mL, 63.7 mmol) were suspended in DCE (88 mL) and stirred overnight. The reaction mixture was purified by column chromatography to give the title compound as an off-white solid (619 mg, 13%). HRMS (ESI+) calcd for C₂₀H₂₁ClN₄O₂ 385.1426, found 385.143. HPLC: Rf 6.13 min, 98.9% purity.

EXAMPLE 12


Ethyl 1-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate



Example 12 was prepared similarly to Example 11, using 4-methylbenzeneboronic acid instead of 4-chlorophenylboronic acid, to give the title compound as a white solid (74.0 mg, 56%). HRMS (ESI+) calcd for C₂₁H₂₄N₄O₂ 365.1972, found 365.1975. HPLC: Rf 5.87 min, 99.1% purity.


EXAMPLE 13

1-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid hydrochloride



Example 11 (834 mg, 2.17 mmol) was dissolved in 1:1 THF/water (16 mL), LiOH.H₂O (200 mg, 4.77 mmol) was added and the reaction mixture was stirred for 3 h. The THF was removed *in vacuo* and the reaction mixture was acidified to pH 1 with 1 M aq HCl (5 mL). The precipitate was collected by filtration and washed with water to give the title compound as an orange solid (450 mg, 53%). HRMS (ESI+) calcd for C₁₈H₁₇ClN₄O₂ 357.1113, found 357.1112. HPLC: Rf 4.92 min, 99.6% purity.


EXAMPLE 14

N-(2-Aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide dihydrochloride

5 Example 13 (200 mg, 0.51 mmol) was dissolved in DMF (2 mL), HBTU (231 mg, 0.61 mmol) was added and the reaction mixture was stirred for 30 min. *tert*-Butyl N-(2-aminoethyl)carbamate (97.8 mg, 0.61 mmol) and DIPEA (266 mL, 1.53 mmol) were added and the reaction mixture was stirred overnight. The reaction mixture was concentrated *in vacuo* and triturated twice from EtOAc (25 mL) and MeOH (10mL). The residue was dissolved in
10 1.25 M HCl in EtOH (5 mL), stirred for 20 h and concentrated *in vacuo* to yield the title compound as an orange solid (50.1 mg, 95%). HRMS (ESI+) calcd for C₂₀H₂₃ClN₆O 399.1695, found 399.1694. HPLC: R_f 3.96 min, 99.8% purity.

EXAMPLE 15


15 **4-({1-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)morpholine**



Example 15 was prepared similarly to Example 14, using morpholine instead of *tert*-Butyl N-(2-aminoethyl)carbamate (and no deprotection step) to give the title compound as a light
20 yellow solid (78.7 mg, 36%). HRMS (ESI+) calcd for C₂₂H₂₄ClN₅O₂ 426.1691, found 426.1691. HPLC: R_f 4.96 min, 100% purity.

EXAMPLE 16


25 **1-({1-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)piperazine dihydrochloride**



Example 16 was prepared similarly to Example 14, using *tert*-Butyl 1-piperazinecarboxylate instead of *tert*-Butyl N-(2-aminoethyl)carbamate to give the title compound as an orange solid (122 mg, 96%). HRMS (ESI+) calcd for C₂₂H₂₅ClN₆O 425.1851, found 425.1846. HPLC: Rf 3.98 min, 98.8% purity.

EXAMPLE 17


{4-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}methanol



Intermediate 21 (50.0 mg, 0.14 mmol) was dissolved in MeOH (1 mL), K₂CO₃ (75.4 mg, 0.55 mmol) was added and the reaction mixture was stirred for 30 min. The reaction mixture was concentrated *in vacuo* and the residue partitioned between DCM (10 mL) and water (5 mL). The aq fraction was extracted with DCM (3 x 10 mL) and the combined organic fractions were dried (MgSO₄) and concentrated *in vacuo* to give the title compound as a yellow gum (40.0 mg, 90%). LCMS (ES⁺): 325.1 [MH]⁺. HPLC: Rf 4.36 min, 94.9% purity.


EXAMPLE 18

{4-[1-(4-Methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methanol




Example 18 was prepared similarly to Example 17, using Intermediate 22 instead of Intermediate 21, to give the title compound as an orange gum (3.74 mg, 36%). HRMS (ESI+) calcd for C₁₈H₂₀N₄O₂ 325.1659, found 325.1663. HPLC: Rf 4.29 min, 98.8% purity.


EXAMPLE 19

[(3R)-4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]methanol

Example 19 was prepared similarly to Example 11, using Intermediate 15 instead of Intermediate 13, to give the title compound as a dark yellow gum (11.6 mg). HRMS (ESI+) calcd for C₁₇H₁₇ClN₄O₂ 345.1113, found 345.1117. HPLC: R_f 4.58 min, 100% purity.

EXAMPLE 20**Methyl 4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxylate**


Example 20 was prepared similarly to Example 11, using Intermediate 18 instead of Intermediate 13, to give the title compound as a dark yellow solid (552 mg, 20%). HRMS (ESI+) calcd for C₁₈H₁₇ClN₄O₃ 373.1062, found 373.1065. HPLC: R_f 5.23 min, 98.0% purity.

EXAMPLE 21**N-(2-Aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxamide**

Intermediate 25 (70.0 mg, 0.18 mmol) was dissolved in DMF (1.1 mL), cooled to 0 °C and HBTU (67.2 mg, 0.18 mmol), *tert*-butyl N-(2-aminoethyl)carbamate (34.1 mg, 0.21 mmol) and DIPEA (30.9 μL, 0.18 mmol) were added. The reaction mixture was stirred at 0 °C for 2.5 h and purified by column chromatography. The residue dissolved in 1.25 M HCl in EtOH (1.00 mL) and stirred for 2 h. The reaction mixture was concentrated *in vacuo* and purified by


column chromatography to give the title compound as a pale yellow solid (3.09 mg, 4%). HRMS (ESI+) calcd for C₁₉H₂₁CIN₆O₂ 401.1487, found 401.149. HPLC: R_f 3.83 min, 100% purity.

5 EXAMPLE 22

2-[4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]ethan-1-ol

Intermediate 24 (50.0 mg, 0.13 mmol) was dissolved in DCM (1 mL), cooled to 0 °C and DIBALH (0.47 mL, 1.0 M in heptane, 0.47 mmol) was added drop-wise. The reaction mixture was stirred for 48 h, cooled to 0 °C and quenched with sat aq NaHCO₃ (1 mL). The reaction mixture was extracted with DCM (5 x 20 mL) and the combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by reverse phase chromatography to give the title compound as a pale yellow solid (13.9 mg, 30%). HRMS (ESI+) calcd for C₁₈H₁₉CIN₄O₂ 359.1269, found 359.1274. HPLC: R_f 4.72 min, 99.5% purity.


EXAMPLE 23

Methyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxylate

20 Example 23 was prepared similarly to Example 11, using Intermediate 20 instead of Intermediate 13, to give the title compound as a dark yellow solid (260 mg, 28%). HRMS (ESI+) calcd for C₁₉H₁₉CIN₄O₂ 371.1269, found 371.1273. HPLC: R_f 5.91 min, 99.3% purity.

25 EXAMPLE 24

N-(2-Aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxamide dihydrochloride




Example 24 was prepared similarly to Example 21, using Intermediate 26 instead of Intermediate 25, to give the title compound as an orange solid (22.5 mg, 28%). LCMS (ES+): 399.0 [MH]⁺. HPLC: Rf 4.10 min, 98.5% purity.

5

EXAMPLE 25


1-((1-(1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl)piperidin-2-yl)carbonyl)piperazine



10 Example 25 was prepared similarly to Example 24, using *tert*-butyl 1-piperazinecarboxylate instead of *tert*-butyl *N*-(2-aminoethyl)carbamate, to give the title compound as a yellow solid (10.3 mg, 14%). LCMS (ES+): 424.9 [MH]⁺. HPLC: Rf 3.91 min, 99.5% purity.

EXAMPLE 26

15 4-[1-(4-Methylphenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine




Intermediate 31 (81.0 mg, 0.40 mmol), 4-iodotoluene (104 mg, 0.48 mmol), *N,N*-dimethylethylenediamine (8.58 μ L, 0.08 mmol) and K₃PO₄ (178 mg, 0.84 mmol) were suspended in DMF (1 mL) and CuI (7.60 mg, 0.04 mmol) was added. The reaction mixture was heated at 170 °C in a microwave reactor for 1 h and concentrated *in vacuo*. The residue was diluted with MeOH (15 mL), filtered, concentrated *in vacuo* and purified by reverse phase

20


HPLC and normal phase column chromatography to give the title compound as a dark yellow gum (2.00 mg, 2%). HRMS (ESI+) calcd for C₁₈H₁₉N₃O 294.1601, found 294.1604. HPLC: Rf 4.43 min, 100% purity.

5 EXAMPLE 27

1-(4-Chlorophenyl)-3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-4-ol

Intermediate 36 (130 mg, 0.29 mmol) was dissolved in DCM (10 mL), BBr₃ (84 μL, 0.88 mmol) was added and the reaction mixture was stirred for 3 h, quenched with 1 M aq NaOH (1 mL) and stirred for 1 h. The reaction mixture was diluted with sat aq NaHCO₃ (25 mL) and extracted with DCM (3 x 25 mL). The aq fraction was acidified to pH 9 with AcOH and extracted with EtOAc (2 x 25 mL). The combined organic fractions were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by reverse phase HPLC to give the title compound as a colourless gum (8.40 mg, 9%). HRMS (ESI+) calcd for C₁₈H₁₈ClN₃O 328.1211, found 328.1216. HPLC: Rf 3.70 min, 89% purity.


EXAMPLE 28

N-Butyl-1-(4-chlorophenyl)-N-methyl-1H-pyrazolo[3,4-c]pyridin-3-amine

20 Example 28 was prepared similarly to Example 26, using Intermediate 17 instead of Intermediate 31, and 1-chloro-4-iodobenzene instead of 4-iodotoluene, to give the title compound as a yellow gum (212 mg, 22%). HRMS (ESI+) calcd for C₁₇H₁₉ClN₄ 315.1371, found 315.1375. HPLC: Rf 6.54 min, 100% purity.

25 EXAMPLE 29


1-[4-(Fluoromethyl)phenyl]-3-(oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine



Example 29 was prepared similarly to Example 26, using Intermediate 39 instead of Intermediate 31, and 1-bromo-4-fluoromethylbenzene instead of 4-iodotoluene, to give the title compound as a yellow gum (36.6 mg, 7%). HRMS (ESI+) calcd for C₁₈H₁₈FN₃O 312.1507, found 312.151. HPLC: R_f 4.84 min, 99.2% purity.

EXAMPLE 30

3-((4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl)methyl)pyridine



Intermediate 44 (232 mg, 0.74 mmol) was dissolved in DCM (25 mL) and 3-pyridinecarboxaldehyde (167 μ l, 1.78 mmol), AcOH (44.6 μ L, 0.78 mmol) and NaBH(OAc)₃ (472 mg, 2.23 mmol) were added. The reaction was stirred for 18 h, diluted with DCM (50 mL) and quenched with water (20 mL). The organic fraction was washed with sat aq Na₂CO₃ (20 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by reverse phase HPLC to give the title compound as a brown gum (63.7 mg, 21 %). HRMS (ESI+) calcd for C₂₃H₂₂CIN₅ 404.1636, found 404.1639. HPLC: R_f 4.63 min, 98.3% purity.

BIOLOGICAL TESTS

Biological Assays of the SSAO Enzyme Inhibitors

All primary assays were performed at RT. with purified recombinantly expressed human SSAO. Enzyme was prepared essentially as described in Öhman et al. (Protein Expression and Purification **46** (2006) 321–331). In addition, secondary- and selectivity assays were performed using SSAO prepared from various tissues or purified rat recombinant SSAO. The enzyme activity was assayed with benzylamine as substrate by measuring either benzaldehyde production, using ¹⁴C-labeled substrate, or by utilizing the production of hydrogen peroxide in a horseradish peroxidase (HRP) coupled reaction. Briefly, test compounds were dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mM. Dose-response measurements were

assayed by either creating 1:10 serial dilutions in DMSO to produce a 7 point curve or by making 1:3 serial dilutions in DMSO to produce 11 point curves. The top concentrations were adjusted depending on the potency of the compounds and subsequent dilution in reaction buffer yielded a final DMSO concentration $\leq 2\%$.

5

Hydrogen peroxide detection:

In a horseradish peroxidase (HRP) coupled reaction, hydrogen peroxide oxidation of 10-acetyl-3,7-dihydroxyphenoxazine produced resorufin, which is a highly fluorescent compound (Zhou and Panchuk-Voloshina. *Analytical Biochemistry* **253** (1997) 169-174; Amplex[®] Red Hydrogen Peroxide/peroxidase Assay kit, Invitrogen A22188). Enzyme and compounds in 50 mM sodium phosphate, pH 7.4 were set to pre-incubate in flat-bottomed microtiter plates for approximately 15 minutes before initiating the reaction by addition of a mixture of HRP, benzylamine and Amplex reagent. Benzylamine concentration was fixed at a concentration corresponding to the Michaelis constant, determined using standard procedures. Fluorescence intensity was then measured at several time points during 1 – 2 hours, exciting at 544 nm and reading the emission at 590 nm. For the human SSAO assay final concentrations of the reagents in the assay wells were: SSAO enzyme 1 $\mu\text{g/ml}$, benzylamine 100 μM , Amplex reagent 20 μM , HRP 0.1 U/mL and varying concentrations of test compound. The inhibition was measured as % decrease of the signal compared to a control without inhibitor (only diluted DMSO). The background signal from a sample containing no SSAO enzyme was subtracted from all data points. Data was fitted to a four parameter logistic model and IC_{50} values were calculated using the GraphPad Prism 4 or XLfit 4 programs.

Aldehyde detection:

SSAO activity was assayed using ^{14}C -labeled benzylamine and analysed by measuring radioactive benzaldehyde. In a white 96-well optiplate (Packard), 20 μL of diluted test compound was pre-incubated at RT. with 20 μL SSAO enzyme for approximately 15 minutes with continuous agitation. All dilutions were made with PBS. The reaction was initiated by adding 20 μL of the benzylamine substrate solution containing [7- ^{14}C] Benzylamine hydrochloride (CFA589, GE Healthcare). The plate was incubated for 1 hour as above after which the reaction was stopped by acidification (10 μL 1 M HCl). Then 90 μL Micro Scint-E solution (Perkin-Elmer) was added to each well and the plate was continuously mixed for 15 minutes. Phase separation occurred instantly and activity was read in a Topcount scintillation counter (Perkin-Elmer). In the final reaction well, the human recombinant SSAO concentration was 10 $\mu\text{g/ml}$. In order to optimize sensitivity, the substrate concentration was decreased as

35

compared to the HRP coupled assay in order to get a higher fraction of radioactive product. In the human SSAO assay, benzylamine concentration was 40 μM (0.2 $\mu\text{Ci/mL}$). Data was analysed as above.

- 5 All of the exemplified compounds of the invention had an IC_{50} value of 1-2500 nM at SSAO (See Table 4).

Table 4: SSAO inhibitory activity

(A: <100nM, B: 100-500nM, C: 500-2500nM)

Compound	IC_{50} (nM)	Compound	IC_{50} (nM)	Compound	IC_{50} (nM)
1	A	11	C	21	A
2	A	12	B	22	A
3	A	13	B	23	C
4	A	14	B	24	A
5	A	15	C	25	A
6	A	16	B	26	B
7	A	17	A	27	A
8	A	18	A	28	C
9	B	19	A	29	B
10	A	20	B	30	B

CLAIMS

1. A compounds selected from the group consisting of:

- 2-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}ethan-1-amine;
 5 3-aminopropyl 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxylate;
 1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}-4-(dimethylamino)butan-1-one;
 5-amino-1-{4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}pentan-1-one;
 N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-
 10 carboxamide;
 N-(3-aminopropyl)-4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidine-1-carboxamide;
 4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine-1-carboxamide;
 15 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)piperazine;
 4-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)morpholine;
 1-({4-[1-(4-chlorophenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl}carbonyl)-1,4-diazepane;
 ethyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate;
 20 ethyl 1-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate;
 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid ;
 N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide;
 4-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-
 25 yl}carbonyl)morpholine;
 1-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)piperazine;
 {4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}methanol;
 {4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methanol;
 [(3R)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]methanol;
 30 methyl 4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxylate;
 N-(2-aminoethyl)-4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3-carboxamide;
 2-{4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl}ethan-1-ol;
 methyl 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxylate;

N-(2-aminoethyl)-1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxamide;
1-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-yl}carbonyl)piperazine;
4-[1-(4-methylphenyl)-1H-pyrrolo[2,3-c]pyridin-3-yl]morpholine;
5 1-(4-chlorophenyl)-3-(piperidin-4-yl)-1H-pyrrolo[2,3-c]pyridin-4-ol;
N-butyl-1-(4-chlorophenyl)-N-methyl-1H-pyrazolo[3,4-c]pyridin-3-amine;
1-[4-(fluoromethyl)phenyl]-3-(oxan-4-yl)-1H-pyrazolo[3,4-c]pyridine;
3-({4-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}methyl)pyridine;

10 and pharmaceutically acceptable salts thereof.

2. A pharmaceutical composition comprising a compound as claimed in claim 1, together with one or more pharmaceutically acceptable carriers and/or excipients

15 3. A compound as claimed in claim 1 for use in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.

4. The use of a compound as claimed in claim 1 in the manufacture of a composition for treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or
20 inhibition of tumour growth.

5. A method for the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth, which comprises administering to a subject suffering such disease an effective amount of a compound as claimed in claim 1.

25

6. A compound as claimed in claim 1, or use as claimed in claim 4, or the method as claimed in claim 5 wherein the inflammation or inflammatory disease or immune or autoimmune disorder is arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis and psoriatic arthritis), synovitis, vasculitis, a condition associated with
30 inflammation of the bowel (including Crohn's disease, ulcerative colitis, inflammatory bowel disease and irritable bowel syndrome), atherosclerosis, multiple sclerosis, Alzheimer's disease, vascular dementia, a pulmonary inflammatory disease (including asthma, chronic obstructive pulmonary disease and acute respiratory distress syndrome), a fibrotic disease (including idiopathic pulmonary fibrosis, cardiac fibrosis and systemic sclerosis (scleroderma)), an
35 inflammatory disease of the skin (including contact dermatitis, atopic dermatitis and psoriasis),

systemic inflammatory response syndrome, sepsis, an inflammatory and/or autoimmune condition of the liver (including autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, sclerosing cholangitis, and autoimmune cholangitis), diabetes (type I or II) and/or the complications thereof, chronic heart failure, congestive heart failure, an ischemic disease
5 (including stroke and ischemia-reperfusion injury) or myocardial infarction and/or the complications thereof.

7. A compound as claimed in claim 1, or use as claimed in claim 4, or method as claimed in claim 5, wherein the inflammatory disease is rheumatoid arthritis, chronic obstructive pulmonary disease or atopic dermatitis.

8. A compound as claimed in claim 1, or use as claimed in claim 4, or the method as claimed in claim 5 for inhibition of tumour growth.

INTERNATIONAL SEARCH REPORT

International application No PCT/EP2011/065967

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C07D471/04 A61K31/437
 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2010/031791 A1 (BIOVITRUM AB PUBL [SE]; SAVORY EDWARD [GB]; SIMPSON IAIN [GB]) 25 March 2010 (2010-03-25) the whole document -----	1-8
A	WO 2010/064020 A1 (PROXIMAGEN LTD [GB]; NILSSON MARIANNE [SE]; HARALDSSON MARTIN [SE]; HE) 10 June 2010 (2010-06-10) the whole document -----	1-8
A	WO 02/38153 A1 (BIOVITRUM AB [SE]; CALDIROLA PATRIZIA [SE]; BESENCON OLIVIER [CH]; OLS) 16 May 2002 (2002-05-16) the whole document -----	1-8
	----- -/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

14 October 2011

Date of mailing of the international search report

21/10/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016

Authorized officer

Usuelli, Ambrogio

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2011/065967

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 2011/113798 A2 (PROXIMAGEN LTD [GB]; EVANS DAVID [GB]; CARLEY ALLISON [GB]; STEWART AL) 22 September 2011 (2011-09-22) cited in the application the whole document -----	1-8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2011/065967

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010031791 A1	25-03-2010	EP 2328895 A1 US 2011195992 A1	08-06-2011 11-08-2011

WO 2010064020 A1	10-06-2010	NONE	

WO 0238153 A1	16-05-2002	AU 1450502 A	21-05-2002

WO 2011113798 A2	22-09-2011	NONE	
